External links open in a new tab. TheraCALC links only to publicly available government, institutional, peer-reviewed sources, and indexes. These are reference resources — always verify against your institution's formulary and protocols.
🧫 Aminoglycosides — Guidelines & PK Literature Extended-interval & obesity dosing
Nicolau et al. 1995 — Hartford Once-Daily Program
Nicolau DP et al. Antimicrob Agents Chemother 1995;39(3):650–655. The original 2,184-patient once-daily program: fixed 7 mg/kg, CrCl-based starting interval, and the monitoring nomogram (single random level, 6–14 h; borderline levels → longer interval). Basis for TheraCALC's extended-interval path + Hartford nomogram.
PMC
Primary Literature
Smit et al. 2019 — Gentamicin PK in Morbid Obesity
Smit C et al. Clin Pharmacokinet 2019;58(10):1333–1343. Prospective obesity PK: clearance and central volume both weight-dependent, but the clearance exponent (0.73) is lower than the volume exponent (1.25) — clearance is the less weight-dependent of the two. Supports the smaller weight-adjustment on the clearance side.
PMC
Primary Literature
Smit et al. 2020 — Gentamicin Dosing in Obesity
Smit C et al. J Antimicrob Chemother 2020;75(11):3286–3292 (open access). Real-world dose recommendations across body weight and renal function; clearance driven primarily by renal function.
doi.org
Primary Literature
Pai et al. 2011 — AG PK in Underweight & Obese Adults
Pai MP, Nafziger AN, Bertino JS. Antimicrob Agents Chemother 2011;55(9):4006–4011. Clearance best predicted by renal function, not total body weight — supporting a conservative weight-adjustment on the Cockcroft-Gault side.
PubMed
Primary Literature
Märtson et al. 2025 — Antibiotic Dosing in Obesity
Märtson A-G et al. Lancet Infect Dis 2025;25(9). Systematic review + international consensus guidelines for antibiotic dose adjustment in obesity (>120 PK studies).
The Lancet
Consensus Review
🩸 Anticoagulation — Guidelines & Clinical References MAQI2 · ACC/AHA · CHEST · ASRA · ASH
ACC/AHA/ACCP/HRS 2023 AFib Guidelines
2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation. CHA₂DS₂-VASc scoring, anticoagulation selection, and stroke prevention recommendations.
jacc.org
ACC/AHA 2023
CHEST 2022 — Antithrombotic Therapy
American College of Chest Physicians antithrombotic guidelines. VTE treatment, periprocedural management, and bridging recommendations.
chestnet.org
CHEST 2022
PAUSE Trial — DOAC Periop Interruption
Douketis et al., JAMA Intern Med 2019. Standardized DOAC interruption without heparin bridging for elective procedures. Foundation for TheraCALC DOAC hold calendar logic.
doi.org
JAMA 2019
ASRA 2025 — Neuraxial & Deep Block Guidelines
American Society of Regional Anesthesia guidelines for anticoagulant management in patients receiving neuraxial or deep peripheral nerve blocks. DOAC and heparin hold times. Fifth edition (Kopp et al., Reg Anesth Pain Med 2025).
pubmed.ncbi.nlm.nih.gov
ASRA 2025
ASH Guidelines — Heparin-Induced Thrombocytopenia
American Society of Hematology 2018 HIT guidelines (Cuker et al., Blood Adv 2018). 4T score interpretation, direct thrombin inhibitor selection, and management of suspected or confirmed HIT.
pubmed.ncbi.nlm.nih.gov
ASH 2018
MAQI2 Anticoagulation Toolkit
Michigan Anticoagulation Quality Improvement Initiative. Clinical decision-support tools for warfarin dosing, DOAC management, periprocedural interruption, and HIT. Primary reference source for TheraCALC anticoagulation content.
anticoagulationtoolkit.org
Clinical Toolkit
💊 Pain Management & Opioids — Guidelines & Clinical References CDC · FDA · APS · ASHP
CDC 2022 Clinical Practice Guideline — Prescribing Opioids for Pain
Dowell D, Ragan KR, Jones CM, et al. MMWR Recomm Rep 2022;71(3):1–95. The primary framework for the toolkit: MME thresholds, initiation & titration, naloxone co-prescribing, breakthrough dosing, and risk mitigation. DOI 10.15585/mmwr.rr7103a1.
cdc.gov/mmwr
CDC 2022
CDC — Calculating Total Daily Dose (MME)
CDC conversion factors used in the MME calculator and the equianalgesic quick table. Notes the analytic intent of MME and the exclusion of parenteral fentanyl, methadone, and buprenorphine from straightforward conversion.
cdc.gov/overdose-prevention
CDC MME
VA/DoD — Opioid Therapy for Chronic Pain CPG
Department of Veterans Affairs / Department of Defense clinical practice guideline. Risk stratification, tapering, and monitoring recommendations referenced in the Learn algorithm and risk sections.
healthquality.va.gov
VA/DoD
Methadone Safety CPG (APS / CPDD / HRS)
Chou R, Cruciani RA, Fiellin DA, et al. J Pain 2014;15(4):321–337. Basis for the methadone pearls: dose-dependent conversion ratios, QTc/ECG monitoring, and "start low, go slow" titration. DOI 10.1016/j.jpain.2014.01.494.
pubmed.ncbi.nlm.nih.gov
J Pain 2014
McPherson — Demystifying Opioid Conversion Calculations (ASHP)
McPherson ML. ASHP, 2nd ed. 2018. Source for the PCA starting parameters (demand, loading, lockout, continuous ranges) and the rotation/cross-tolerance methodology used throughout the toolkit.
ashp.org
ASHP 2018
FDA Prescribing Information (DailyMed)
Official FDA labeling for Belbuca, Butrans, OxyContin, Exalgo, Duragesic, and others. Source for buprenorphine taper-to-≤30-MME conversion, ER dosing intervals, opioid-tolerant definitions, and dispensable strengths.
dailymed.nlm.nih.gov
FDA
Opioid Risk Tool (ORT) — Webster 2005
Webster LR, Webster RM. Pain Med 2005;6(6):432–442. Sex-weighted OUD risk screening instrument reproduced in the Risk & Safety section. DOI 10.1111/j.1526-4637.2005.00072.x.
pubmed.ncbi.nlm.nih.gov
Pain Med 2005
WHO Guidelines — Cancer Pain & Analgesic Ladder
World Health Organization guidelines for the pharmacological management of cancer pain. Basis for the three-step analgesic ladder and adjuvant/co-analgesic guidance in the Learn algorithm.
who.int
WHO
StatPearls — Opioid Equivalency
Peer-reviewed open reference (NCBI Bookshelf) on equianalgesic conversion and incomplete cross-tolerance. Supports the rotation reduction logic and IV→PO breakthrough sizing.
ncbi.nlm.nih.gov/books
StatPearls
Opioid Toolkit — verification provenance. The toolkit's calculations and clinical content are source-checked against the references above — conversion factors against the CDC 2022 CPG, FDA-label values against current prescribing information, and the ORT, methadone, and rotation guidance against their primary sources. Verification confirms each value matches an authoritative source; it does not certify safety for an individual patient, and guidelines and labels change — confirm against current sources before clinical use.